SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is seeing intense investor focus as geopolitical instability in the Middle East disrupts global LNG supplies, positioning the company as a key supplier for energy-dependent European markets. The community is actively debating the stock's potential for a short squeeze amid high borrow rates and low float, while closely monitoring technical price action and potential energy infrastructure developments.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is facing intense backlash and bearish sentiment from investors following the announcement of a reverse stock split, with many in the community viewing the move as a "kiss of death" for the struggling streaming platform. Discussions are heavily focused on the company's lack of key sports networks, dwindling subscriber confidence, and frustration toward leadership, leading many traders to actively initiate or hold short positions.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is trending as investors digest mixed results from its Phase 3 SENTRY trial in myelofibrosis, which met spleen volume reduction goals but missed on key symptom endpoints. Community discourse is highly polarized, with some highlighting the strong overall survival signal as a potential path for future regulatory success, while others express deep frustration over the company's financial runway and recent private placement deals.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as a highly speculative, low-cap meme coin that has polarized the community, with some traders touting its potential for explosive gains while others warn it is a classic pump-and-dump scheme. Discussion centers on its rapid price volatility, accessibility via DEX platforms, and ongoing debate over whether its current price action reflects genuine accumulation or manipulative tactics by top holders.

Cantor Equity Partners II, Inc. is a blank check company. The company was founded on November 11, 2020 and is headquartered in New York, NY

Cantor Equity Partners II Inc. - Ordinary Shares - Class A

Cantor Equity Partners II Inc

Investors are closely tracking Cantor Equity Partners II as it nears its business combination with Securitize, the infrastructure provider behind major institutional tokenization projects like BlackRock's BUIDL fund. Market participants are treating the stock as a pure-play opportunity for the real-world asset (RWA) tokenization sector, with many discussing the long-term growth potential and institutional backing from major financial players.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is trending as investors react to the company's newly authorized $1 billion share repurchase program, which will be valid through March 2027. While some market participants interpret the buyback as a sign of management's confidence and a potential boost to earnings per share, others remain focused on the company's valuation struggles, intense competition in the Chinese EV market, and ongoing debates regarding the efficacy of its charging technology compared to battery-swapping alternatives.

Smithfield Foods, Inc. operates as a meat-processing company. The firm processes and produces pork and hog. Its brands include Smithfield, Eckrich, Nathan's Famous, Farmland, and Armour. The company was founded by Joseph Williamson Luter, Sr. and Joseph Williamson Luter, Jr. in 1936 and is headquartered in Smithfield, VA.

Smithfield Foods, Inc.

Smithfield Foods Inc.

Smithfield Foods is trending as investors react to the companys recent earnings beat, which showcased strong growth in the packaged meats segment and a dividend increase. The community is actively discussing the stock's long-term potential, including its recent acquisition of Nathan's Famous and its strategic positioning in the protein sector despite ongoing debates surrounding industry ownership.

NETGEAR, Inc. engages in the provision of networking technologies for businesses, homes, and service providers. It operates through the Connected Home and NETGEAR for Business segments. The Connected Home segment offers WiFi networking solutions such as 4G/5G mobile products, WiFi 7 Tri-band and Quad-band mesh systems and routers, WiFi 6E, WiFi 6, and subscription services. The NETGEAR for Business segment consists of networking solutions, including switches, routers, access points, software, and AV over IP technologies. The company was founded by Patrick C. S. Lo and Mark G. Merrill on January 8, 1996, and is headquartered in San Jose, CA.

Netgear Inc

Netgear is seeing significant market attention as U.S. regulators take action against foreign-made routers, fueling community discussion regarding the company's competitive standing and potential market share gains. While traders debate the stock's turnaround potential and its exposure to ongoing supply chain and geopolitical risks, some investors are highlighting the company's valuation relative to its cash position as a key point of interest.

Apollo Global Management, Inc. provides asset management services. It offers its clients excess return at every point along the risk-reward spectrum from investment grade to private equity with a focus on three business strategies: yield, hybrid, and equity. It operates through following segments: Asset Management, Retirement Services and Principal Investing. The Asset Management segment focuses on credit and equity investing strategies. The Retirement Services and Principal Investing segment consists of realized performance fee income, realized investment income from balance sheet investments, and certain allocable expenses related to corporate functions supporting the entire company. The company was founded by Marc Rowan in 1990 and is headquartered in New York, NY.

Apollo Global Management Inc

Apollo Global Management is experiencing heightened market attention following reports that CEO Marc Rowan is a key contender for U.S. Treasury Secretary, a development that has fueled investor optimism regarding the potential for deregulation. Meanwhile, the stock continues to benefit from institutional interest and strong earnings momentum that has bolstered its status as a major player in private markets and credit.

Jefferies Financial Group, Inc. is a holding company, which engages in the provision of financial services. It operates through Investment Banking and Capital Markets, and Asset Management. The Investment Banking and Capital Markets segment involves the provision of underwriting and financial advisory services in the Americas, Europe and the Middle East, and Asia-Pacific. The Asset Management segment includes investing seed and additional strategic capital. The company was founded in 1968 and is headquartered in New York, NY.

Jefferies Financial Group Inc

Jefferies Financial Group shares are gaining traction as the company capitalizes on an ongoing rebound in capital markets and investment banking activity. The community is focused on the bank's strategic alliance with SMFG, which continues to drive speculation about potential stake increases and cross-border expansion, while traders debate whether the stock's recent price action signals a sustainable trend or just a reflection of broader banking sector volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In this photo illustration, the Tempest Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction

The transaction is expected to close in early 2026, provided it receives all required approvals. 

Equity

The transaction is expected to close in early 2026, provided it receives all required approvals. 


Why Tempest Therapeutics (TPST) Stock Is Down 45% Today

Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience.read more...

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

Shares of Tempest Therapeutics (TPST) ended higher on Wednesday amid a broader market rebound on the U.S. pausing tariffs and extended gains after-hours after the company said it was exploring strategic alternatives.&nbsp;The cancer drug developer said its options included a merger, acquisition, partnership, or licensing deal to advance its pipeline and maximize shareholder value.&nbsp;The company has retained MTS Health Partners to assist with the process.CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat showing a six-month survival benefit in advanced liver cancer and FDA clearance for a pivotal Phase 3 study.&nbsp;However, Brady said capital markets "have been unavailable to support the next stage of advancement."On Stocktwits, sentiment for Tempest surged into the 'extremely bullish' zone from 'neutral' a day ago, accompanied by message volume soaring over 135% in the 24 hours to late Wednesday.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/TPST_sentiment_and_message_volume_April_9_png_4939200400.webp" alt="TPST sentiment and message volume April 9.png" width="1318" height="316"><figcaption>TPST sentiment and message volume April 9. | source: Stocktwits</figcaption></figure>One user said the CEO was "soliciting bidders" through this move following the recent 1-for-13 reverse stock split."Poison pill is still at $25. Now, anyone who wants more than a 10 percent ownership stake can buy whatever they want at $25 or more. Well played, Mr. Brady!" they wrote.<stembedurl>https://stocktwits.com/xyz1232/message/611152790</stembedurl>Another pinned hopes on "well-known" MTS Partners fetching a good merger deal for Tempest. "Even If TPST gets a below-average deal at $360 million, we're still looking at $100 per share."<stembedurl>https://stocktwits.com/GreylockSec/message/611168891</stembedurl>Amezalpat, Tempest's lead candidate, has received both Orphan Drug and Fast Track designations from the FDA.&nbsp;TPST-1495, a dual EP2/EP4 antagonist, is also advancing toward a Phase 2 trial in familial adenomatous polyposis (FAP) with NCI support.<a href="https://stocktwits.com/symbol/TPST">Tempest Therapeutics stock</a> has lost over 34% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger

CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study. 

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

TPST
Tempest Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TPST News

TPSTTempest Therapeutics Inc